SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

11258	Companies
250090	Keywords
178521	Articles
135978	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 03/28/2025 at 07:00, 1 year 7 months ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD

Japan COPD Dupixent Phase 3 Results Biologic Medicine
PRESS RELEASE

published on 03/24/2025 at 19:27, 1 year 7 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/24/2025 at 07:35, 1 year 7 months ago

Sanofi launches the “Q1 2025 Aide mémoire” document

Financial Results Investors Sanofi Q1 2025 Memory Aid
PRESS RELEASE

published on 03/24/2025 at 07:30, 1 year 7 months ago

Press Release: Availability of the Q1 2025 Aide mémoire
Sanofi announced the availability of the Q1 2025 Aide mémoire on its website to assist in financial modeling, including non-comparable items and first quarter reminders

Sanofi Financial Modeling Aide Mémoire Q1 2025 Exclusivity Losses
PRESS RELEASE

published on 03/10/2025 at 21:09, 1 year 7 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/08/2025 at 19:05, 1 year 7 months ago

Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid

Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
PRESS RELEASE

published on 03/08/2025 at 19:00, 1 year 7 months ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU

Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission
BRIEF

published on 02/25/2025 at 07:05, 1 year 8 months ago

Sarclisa Gains Approval in Japan for Multiple Myeloma Treatment

Multiple Myeloma Sarclisa Approval Sanofi Oncology Japan Healthcare IMROZ Study
PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 8 months ago

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for newly diagnosed multiple myeloma patients, offering new treatment options based on positive IMROZ phase 3 study results

Oncology Japan Multiple Myeloma Sarclisa IMROZ Study
PRESS RELEASE

published on 02/24/2025 at 21:27, 1 year 8 months ago

Sanofi: Disclosure of trading in own shares

Accesswire

Published on 11/02/2026 at 17:00, 4 hours 23 minutes ago

PPX Mining Initiates Operating Permit Process for Igor Processing Plant
Published on 11/02/2026 at 17:00, 4 hours 23 minutes ago

QNX Launches Global Developer Hackathon with $50,000 in Prizes to Accelerate Innovation in Mission-Critical Systems
Published on 11/02/2026 at 16:15, 5 hours 8 minutes ago

ACCESS Newswire Launches SPOT, Seven AI Agents That Check Every Press Release Before Submission
Published on 11/02/2026 at 15:00, 6 hours 23 minutes ago

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Published on 11/02/2026 at 14:00, 7 hours 23 minutes ago

GameSquare to Report Q3 2026 Financial Results on November 16, 2026

View all ACCESSWIRE

EQS Group

Published on 11/02/2026 at 19:45, 1 hour 38 minutes ago

HE Dr Sultan Al Jaber and Sam Altman highlight energy, AI and investment priorities at ADIPEC 2026 opening
Published on 11/02/2026 at 18:00, 3 hours 23 minutes ago

Helvetia Asset Management Ltd adopts a unified market presence
Published on 11/02/2026 at 17:47, 3 hours 36 minutes ago

Key Figures 31.10.2026
Published on 11/02/2026 at 17:40, 3 hours 43 minutes ago

VALBIOTIS SA: Valbiotis delivers a first order to its Chinese joint venture and targets a commercial launch in China by the end of 2026
Published on 11/02/2026 at 17:30, 3 hours 53 minutes ago

GEVELOT S.A.: Weekly declaration of share buybacks – 11/02/2026 (French only)

Les Echos

Published on 11/02/2026 at 21:08, 15 minutes ago

GROUPE SFPI LIQUIDIDY CONTRAT H1 2026
Published on 11/02/2026 at 18:30, 2 hours 53 minutes ago

Disclosure of transactions in own shares from October 26 to October 30, 2026
Published on 11/02/2026 at 18:17, 3 hours 6 minutes ago

Reporting on share buyback transactions carried out between October 28 and October 29, 2026
Published on 11/02/2026 at 18:00, 3 hours 23 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 11/02/2026 at 17:59, 3 hours 24 minutes ago

Saint-Gobain completes the divestment of its Dahl specialist distribution business in Sweden, Norway and Denmark

View all LES ECHOS COMFI WIRE